Per Fischer

Per Fischer is an accomplished executive with extensive experience in the biopharmaceutical industry. Currently serving as CEO of Minervax ApS since 2010 and Fischer BioConsult ApS since 2003, Per Fischer also holds the position of Entrepreneur In Residence at Novo Holdings and Chairman at Helion Biotech ApS. Prior roles include Licensing Director at Novo Nordisk A/S and CEO of NatImmune A/S and FGP Import. Per Fischer began their career at Novo Nordisk Pharmaceuticals as a Virologist and progressed to Manager of Preclinical Development and Manufacturing at Bavarian Nordic A/S. Educational qualifications include a D.Phil. in Biochemistry from the University of Oxford and an M.Sc. in Experimental Cellular Biology from the University of Southern Denmark. Areas of expertise encompass product opportunity evaluations, business plans, financing, business development, and product development.